Cargando…
CD25 expression could be a prognostic marker of bexarotene monotherapy for cutaneous T‐cell lymphomas
Bexarotene is often administered to phototherapy‐resistant early cutaneous T‐cell lymphoma (CTCL) patients as one of the first‐line therapies in real‐world practice. Since bexarotene reduces the expression of CCR4 in CTCL cells and CCL22 to decrease serum CCL22 levels, bexarotene inhibits the migrat...
Autores principales: | Yamamoto, Jun, Ohuchi, Kentaro, Amagai, Ryo, Roh, Yuna, Endo, Junko, Chiba, Hiromu, Tamabuchi, Erika, Kambayashi, Yumi, Hashimoto, Akira, Asano, Yoshihide, Fujimura, Taku |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233073/ https://www.ncbi.nlm.nih.gov/pubmed/37275413 http://dx.doi.org/10.1002/ski2.222 |
Ejemplares similares
-
Quantitative Analysis of Immune-Reactive Cells among Leukocytes Is Useful for the Diagnosis of Drug Eruptions Caused by Bexarotene
por: Chiba, Hiromu, et al.
Publicado: (2022) -
Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy
por: Kambayashi, Yumi, et al.
Publicado: (2022) -
LL-37 Might Promote Local Invasion of Melanoma by Activating Melanoma Cells and Tumor-Associated Macrophages
por: Ohuchi, Kentaro, et al.
Publicado: (2023) -
Successful Treatment of Advanced Primary Cutaneous Peripheral T-Cell Lymphoma with Oral Bexarotene Monotherapy
por: Sato, Yota, et al.
Publicado: (2018) -
Recurrent, Tumor Mutation Burden-High, Cutaneous Angiosarcoma of the Scalp Treated with Pembrolizumab
por: Amagai, Ryo, et al.
Publicado: (2023)